434 related articles for article (PubMed ID: 32818576)
1. The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?
Mahooti M; Miri SM; Abdolalipour E; Ghaemi A
Microb Pathog; 2020 Nov; 148():104452. PubMed ID: 32818576
[TBL] [Abstract][Full Text] [Related]
2. Effect of probiotics as an immune modulator for the management of COVID-19.
Ray M; Manjunath A; Halami PM
Arch Microbiol; 2023 Apr; 205(5):182. PubMed ID: 37031431
[TBL] [Abstract][Full Text] [Related]
3. Probiotics: A potential immunomodulator in COVID-19 infection management.
Singh K; Rao A
Nutr Res; 2021 Mar; 87():1-12. PubMed ID: 33592454
[TBL] [Abstract][Full Text] [Related]
4. Interindividual immunogenic variants: Susceptibility to coronavirus, respiratory syncytial virus and influenza virus.
Darbeheshti F; Mahdiannasser M; Uhal BD; Ogino S; Gupta S; Rezaei N
Rev Med Virol; 2021 Nov; 31(6):e2234. PubMed ID: 33724604
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
Mirzaei R; Attar A; Papizadeh S; Jeda AS; Hosseini-Fard SR; Jamasbi E; Kazemi S; Amerkani S; Talei GR; Moradi P; Jalalifar S; Yousefimashouf R; Hossain MA; Keyvani H; Karampoor S
Arch Virol; 2021 Jul; 166(7):1819-1840. PubMed ID: 33745067
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of resveratrol against emerging respiratory viral infections.
Filardo S; Di Pietro M; Mastromarino P; Sessa R
Pharmacol Ther; 2020 Oct; 214():107613. PubMed ID: 32562826
[TBL] [Abstract][Full Text] [Related]
7. High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro.
Gard AL; Luu RJ; Miller CR; Maloney R; Cain BP; Marr EE; Burns DM; Gaibler R; Mulhern TJ; Wong CA; Alladina J; Coppeta JR; Liu P; Wang JP; Azizgolshani H; Fezzie RF; Balestrini JL; Isenberg BC; Medoff BD; Finberg RW; Borenstein JT
Sci Rep; 2021 Jul; 11(1):14961. PubMed ID: 34294757
[TBL] [Abstract][Full Text] [Related]
8. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.
Darbandi A; Asadi A; Ghanavati R; Afifirad R; Darb Emamie A; Kakanj M; Talebi M
Int J Infect Dis; 2021 Apr; 105():91-104. PubMed ID: 33578007
[TBL] [Abstract][Full Text] [Related]
9. Probiotics as a biotherapeutics for the management and prevention of respiratory tract diseases.
Debnath N; Kumar A; Yadav AK
Microbiol Immunol; 2022 Jun; 66(6):277-291. PubMed ID: 35462444
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Antiviral and Anti-Inflammatory Activities of
Marchetti M; De Berardis B; Bigioni I; Mariano A; Superti F; Scotto d'Abusco A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982205
[TBL] [Abstract][Full Text] [Related]
11. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract.
Flerlage T; Boyd DF; Meliopoulos V; Thomas PG; Schultz-Cherry S
Nat Rev Microbiol; 2021 Jul; 19(7):425-441. PubMed ID: 33824495
[TBL] [Abstract][Full Text] [Related]
12. Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19.
Manna S; Chowdhury T; Chakraborty R; Mandal SM
Probiotics Antimicrob Proteins; 2021 Jun; 13(3):611-623. PubMed ID: 33226581
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management.
Anka AU; Tahir MI; Abubakar SD; Alsabbagh M; Zian Z; Hamedifar H; Sabzevari A; Azizi G
Scand J Immunol; 2021 Apr; 93(4):e12998. PubMed ID: 33190302
[TBL] [Abstract][Full Text] [Related]
14. Role of probiotics to combat viral infections with emphasis on COVID-19.
Sundararaman A; Ray M; Ravindra PV; Halami PM
Appl Microbiol Biotechnol; 2020 Oct; 104(19):8089-8104. PubMed ID: 32813065
[TBL] [Abstract][Full Text] [Related]
15. Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders.
Shahbazi R; Yasavoli-Sharahi H; Alsadi N; Ismail N; Matar C
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105830
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
17. Intranasal neomycin evokes broad-spectrum antiviral immunity in the upper respiratory tract.
Mao T; Kim J; Peña-Hernández MA; Valle G; Moriyama M; Luyten S; Ott IM; Gomez-Calvo ML; Gehlhausen JR; Baker E; Israelow B; Slade M; Sharma L; Liu W; Ryu C; Korde A; Lee CJ; Silva Monteiro V; Lucas C; Dong H; Yang Y; ; Gopinath S; Wilen CB; Palm N; Dela Cruz CS; Iwasaki A
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2319566121. PubMed ID: 38648490
[TBL] [Abstract][Full Text] [Related]
18. Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens.
Heidari Z; Tajbakhsh A; Gheibihayat SM; Moattari A; Razban V; Berenjian A; Savardashtaki A; Negahdaripour M
Recent Pat Biotechnol; 2021 Oct; 15(2):112-136. PubMed ID: 33874878
[TBL] [Abstract][Full Text] [Related]
19. Community use of antibiotics during the COVID-19 lockdown.
Gagliotti C; Buttazzi R; Ricchizzi E; Di Mario S; Tedeschi S; Moro ML
Infect Dis (Lond); 2021 Feb; 53(2):142-144. PubMed ID: 33073645
[No Abstract] [Full Text] [Related]
20. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season.
Jiang C; Yao X; Zhao Y; Wu J; Huang P; Pan C; Liu S; Pan C
Microbes Infect; 2020; 22(6-7):236-244. PubMed ID: 32405236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
